YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma

BACKGROUND: Traditional systemic chemotherapy does not provide survival benefits in patients with hepatocellular carcinoma (HCC). Molecular targeted therapy shows promise for HCC treatment, however, the duration of effectiveness for targeted therapies is finite and combination therapies offer the po...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Jian, Kong, Fandong, Gao, Jun, Zhang, Qiangbo, Dong, Shuying, Gu, Fang, Ke, Shan, Pan, Bing, Shen, Qiang, Sun, Huichuan, Zheng, Lemin, Sun, Wenbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895679/
https://www.ncbi.nlm.nih.gov/pubmed/24418169
http://dx.doi.org/10.1186/1476-4598-13-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895679/
https://www.ncbi.nlm.nih.gov/pubmed/24418169
http://dx.doi.org/10.1186/1476-4598-13-7

Ejemplares similares